
Crafting a vaccine against RSV (respiratory syncytial virus) has been a minefield for 50 years, but scientists believe they have found the right balance. Researchers at Emory University School of Medicine and Children's Healthcare of Atlanta report that they have engineered a version of RSV that is highly attenuated -- weakened in its ability to cause disease -- yet potent in its ability to induce protective antibodies.













